Novo Nordisk A S annual operating cash flow
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Operating Cash Flow Growth & History (NVO)
Novo Nordisk A S's operating cash flow was kr119.10B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr119.10B | −kr1.87B | −1.54% |
| 2024 | 2024-12-31 | kr120.97B | kr12.06B | +11.07% |
| 2023 | 2023-12-31 | kr108.91B | kr30.02B | +38.06% |
| 2022 | 2022-12-31 | kr78.89B | kr23.89B | +43.43% |
| 2021 | 2021-12-31 | kr55.00B | kr3.05B | +5.87% |
| 2020 | 2020-12-31 | kr51.95B | kr5.17B | +11.05% |
| 2019 | 2019-12-31 | kr46.78B | — | — |
Novo Nordisk A S quarterly operating cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr55.20B | kr13.43B | +32.14% |
| Q1 2026 | 2026-03-31 | kr24.08B | — | — |
| Q4 2025 | 2025-12-31 | kr7.62B | — | — |
| Q3 2025 | 2025-09-30 | kr44.98B | — | — |
| Q2 2025 | 2025-06-30 | kr41.77B | — | — |
Novo Nordisk A S operating cash flow trends
Over the last five fiscal years, Novo Nordisk A S's operating cash flow increased from kr51.95B to kr119.10B, a change of kr67.15B. The latest reported quarter, Q2 2026, shows kr55.20B.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...